Abstract
There are known associations between opioids, obesity, and the gut microbiome, but the molecular connection/mediation of these relationships is not understood. To better clarify the interplay of physiological, genetic, and microbial factors, this study investigated the microbiome and host inflammatory responses to chronic opioid administration in genetically obese, diet-induced obese, and lean mice. Samples of feces, urine, colon tissue, and plasma were analyzed using targeted LC-MS/MS quantification of metabolites, immunoassays of inflammatory cytokine levels, genome-resolved metagenomics, and metaproteomics. Genetic obesity, diet-induced obesity, and morphine treatment in lean mice each showed increases in distinct inflammatory cytokines. Metagenomic assembly and binning uncovered over 400 novel gut bacterial genomes and species. Morphine administration impacted the microbiome’s composition and function, with the strongest effect observed in lean mice. This microbiome effect was less pronounced than either diet or genetically driven obesity. Based on inferred microbial physiology from the metaproteome datasets, a high-fat diet transitioned constituent microbes away from harvesting diet-derived nutrients and towards nutrients present in the host mucosal layer. Considered together, these results identified novel host-dependent phenotypes, differentiated the effects of genetic obesity versus diet induced obesity on gut microbiome composition and function, and showed that chronic morphine administration altered the gut microbiome.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Poudel, Suresh 3 ; Yang, Zamin K. 3 ; Giannone, Richard J. 3
; Choo, James J. 4 ; Podar, Mircea 3
; Baghdoyan, Helen A. 5
; Lydic, Ralph 5
; Hettich, Robert L. 3
1 University of Tennessee, Genome Science and Technology Program, Knoxville, USA (GRID:grid.411461.7) (ISNI:0000 0001 2315 1184); Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, USA (GRID:grid.135519.a) (ISNI:0000 0004 0446 2659)
2 Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, USA (GRID:grid.135519.a) (ISNI:0000 0004 0446 2659); Pain Consultants of East Tennessee, PLLC, Knoxville, USA (GRID:grid.135519.a)
3 Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, USA (GRID:grid.135519.a) (ISNI:0000 0004 0446 2659)
4 Pain Consultants of East Tennessee, PLLC, Knoxville, USA (GRID:grid.135519.a)
5 Oak Ridge National Laboratory, Biosciences Division, Oak Ridge, USA (GRID:grid.135519.a) (ISNI:0000 0004 0446 2659); University of Tennessee, Department of Psychology, Knoxville, USA (GRID:grid.411461.7) (ISNI:0000 0001 2315 1184)





